Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$54M
2 rounds on record
Latest round
$21.6M
Venture round · Jul 2024 · 2 yr ago
Backers
1
Coparion
The money's age
Long since its last round
26 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jul 30, 2024
Raised a round Venture round $21.6M · Agenzia Ansa
Apr 2, 2024
Launched Protembis launches ProtEmbo trial in TAVR · Venturebeat
Mar 26, 2024
Raised a round Series B $32.4M · Venturebeat
Feb 24, 2021
Certified Protembis Announces Completion of 20 Cases in European CE Mark Study With the ProtEmbo Cerebral Protection System · businesswire.com
2013
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Jul 2024 | $21.6M | — | Agenzia Ansa |
| Series B | Mar 2024 | $32.4M | — | Venturebeat |
Registers and programsofficial lists and records that name the company
| Legal entity | Protembis GmbH | its site |
Backed byfrom the funds' portfolios and accelerator catalogs
Coparion Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Before Didero, there was Diderot - and a radical idea about where knowledge lives. This is the story behind the name.
Temporal is an open-source durable execution platform and workflow orchestration engine designed to help developers build reliable…
Voltfang is a German energy company offering ready-to-run battery storage systems and energy trading for businesses. It handles projects…
Jellyfish is the intelligence platform for AI-Integrated engineering, helping R&D teams understand impact, adopt best practices, and make…
Nixo is a software startup that provides an operations platform designed specifically for Forward Deployed Engineers (FDEs). Headquartered…
Uno Platform is the most complete cross-platform .NET UI framework for Web, Mobile, Desktop and Embedded. Boost productivity with Visual…
News
Protembis Announces Formation of New Scientific Advisory Board Comprised of World-Renowned Structural Heart Experts
Protembis, a privately-held emerging cardiovascular medical device company, announced today the establishment of a Scientific Advisory Board (SAB) to provide objective advice and contribute to the strategic plans of the company. Specifically, the SAB will
Read more
Report
Cerebral Embolic Protection - A Next Generation Approach for Contemporary TAVR Practice
Co-Chairs Professor Roxana Mehran MD FACC, FACP, FCCP, FESC, FAHA, FSCAI is an interventional cardiologist and a prominent figure in cardiovascular research. She is a Professor of Medicine, Cardiology, and Population Health Science and Policy at the Icahn
Read more
Report
Report
Protembis receives €20 million backing from the European Investment Bank
The European Investment Bank (EIB) is providing €20 million in venture-debt financing to German medical-technology company Protembis to develop a next-generation device for protecting the brains of patients who undergo certain heart treatments. The fundin
Read more
Report
German Medtech Protembis Gets €20 Million EIB Backing for Technology to Protect Brain During Heart Treatment - Business Wire - Ansa.it
EIB offers Protembis venture debt for next-generation technology to reduce risk of brain injury in patients undergoing catheter-based heart treatment Financing is to complete clinical trials and support marketing of
Read more
Report
Protembis begins patient dosing in the PROTEMBO IDE pivotal trial
Protembis begins patient dosing in the PROTEMBO IDE pivotal trial
Read more
Report
First Patient Enrolled in the PROTEMBO IDE Pivotal Trial
Protembis GmbH (Protembis) a privately-held emerging cardiovascular medical device company, announced today the enrollment of the first patient in the PROTEMBO Investigational Device Exemption (IDE) Pivotal Trial (NCT05873816). The trial will enroll betwe
Read more
Report
Protembis launches ProtEmbo trial in TAVR
Protembis begins the PROTEMBO trial to test its ProtEmbo System against the Sentinel device in TAVR procedures, aiming for superior cerebral protection.
Read more
Report
Protembis: Cardiovascular Medical Device Company Raises €30 Million
Protembis - a privately-held emerging cardiovascular medical device company - announced the completion of a €30 million Series B funding round for supporting the enrollment of the PROTEMBO Investigational Device Exemption (IDE) Pivotal Trial (NCT05873816)
Read more
Report
Show more news